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Purpose. To prospectively compare the performance of James and Boer formula in contrast media (CM) administration, in terms of
image quality and parenchymal enhancement in obese patients undergoing CT of the abdomen.Materials and Methods. Fifty-five
patients with a body mass index (BMI) greater than 35 kg/m2 were prospectively included in the study. All patients underwent 64-
row CT examination and were randomly divided in two groups: 26 patients in Group A and 29 patients in Group B. The amount
of injected CM was computed according to the patient’s lean body weight (LBW), estimated using either Boer formula (Group A)
or James formula (Group B). Patient’s characteristics, CM volume, contrast-to-noise ratio (CNR) of liver, aorta and portal vein,
and liver contrast enhancement index (CEI) were compared between the two groups. For subjective image analysis readers were
asked to rate the enhancement of liver, kidneys, and pancreas based on a 5-point Likert scale. Results. Liver CNR, aortic CNR, and
portal vein CNR showed no significant difference between Group A and Group B (all 𝑃 ≥ 0.177). Group A provided significantly
higher CEI compared to Group B (𝑃 = 0.007). Group A and Group B returned comparable overall subjective enhancement values
(3.54 and vs 3.20, all 𝑃 ≥ 0.199). Conclusions. Boer formula should be the method of choice for LBW estimation in obese patients,
leading to an accurate CM amount calculation and an optimal liver contrast enhancement in CT.
1. Introduction
Contrast media (CM) enhancement, during CT exams, is
influenced by multiple factors: patients and tissue character-
istics, CM type, volume, and concentration, injection time,
and scan timing [1–5]. The easiest CM injection protocol
implemented in clinical practice consists of injecting a fixed
amount of CM [6] or tailoring the CM to patient weight
[1, 4, 7].
The concentration ofCM inparenchymal organs is closely
related to extracellular fluid volume space and plasma [8].
In obese subjects, a large proportion of body weight consists
of adipose tissue, which is poorly perfused compared to
solid parenchymas and in which CM distributes poorly
[9]. Consequently, the adipose tissue does not substantially
contribute to contrast distribution. Therefore, such approach
can result in an over- or underdosage of CM in the obese
population [10].
Boer [11] and Peters et al. [12] reported that lean body
weight (LBW) better correlates with extracellular fluid vol-
ume rather than total body weight (TBW). This parameter
has been demonstrated to better estimate the optimal CM
dose calculation compared to TBW, reducing also patient-
to-patient variability [13, 14]. However, LBW is not currently
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calculated with consistency among investigators. In fact,
several formulas [11, 13, 15–17] have been used to serve this
purpose.
While James formula [15] is one of the most widely
applied formulas in clinical practice [18], despite general
agreements in the advantage of using LBW over TBW to
assess the right amount of CM, major concerns have been
raised regarding the optimal formulas to be applied in obese
population. In fact, Nyman [19] proposed Boer formula [11]
could better estimate LBW in obese patients.
Therefore, the aim of our study was to prospectively
compare the performance of James andBoer formula in terms
of image quality and parenchymal enhancement in obese
patients.
2. Material and Methods
2.1. Study Population. This prospective, single-center,HIPAA
study was approved by our Institutional Review Board.
Written informed consent was obtained from all subjects
included in our study.
From July 2016 to October 2017 patients referring at
our institution for a multiphasic CT of the abdomen,
including arterial, portal venous, and equilibrium phases,
with a body mass index (BMI) ≥ 35 kg/m2, were enrolled
in this study. Exclusion criteria were as follows: age <
18 years, previous reactions to iodinated intravenous CM,
impaired renal function (estimated glomerular filtration rate< 30 mL/min/1.73m2) or any other contraindication to CM
injection, intravenous access smaller than 18 gauge, and
pregnancy. Patient sex, age, height, weight, body mass index
(BMI), and LBW were recorded.
2.2. Patient Randomization and Lean Body Weight Calcula-
tion. Patients were randomized into two groups with a 1:1
ratio. All the individuals allocated in Group A had the LBW
calculated applying Boer formula [11], according to patient’s
sex, as follows:
𝐿𝐵𝑊𝐵𝑜𝑒𝑟𝑚𝑎𝑙𝑒 = (0.407 ⋅ 𝑊) + (0.267 ⋅ 𝐻) − 19.2 (1)
𝐿𝐵𝑊𝐵𝑜𝑒𝑟𝑓𝑒𝑚𝑎𝑙𝑒 = (0.252 ⋅ 𝑊) + (0.473 ⋅ 𝐻) − 48.3 (2)
where W represents the patient weight in kilograms and H
the patient height in meters.
All the individuals allocated in Group B had the LBW
calculated applying James formula [15] as follows:
𝐿𝐵𝑊𝐽𝑎𝑚𝑒𝑠𝑚𝑎𝑙𝑒 = (1.10 ⋅ 𝑊) − 128 ⋅ [ 𝑊
2
(100 ⋅ 𝐻)2] (3)
𝐿𝐵𝑊𝐽𝑎𝑚𝑒𝑠𝑓𝑒𝑚𝑎𝑙𝑒 = (1.07 ⋅ 𝑊) − 148 ⋅ [ 𝑊
2
(100 ⋅ 𝐻)2] (4)
where W represents the patient weight in kilograms and H
the patient height in meters.
2.3. CT Image Acquisition. All examinations were performed
using a 64-row multidetector CT scanner (Lightspeed VCT,
GE Medical Systems, Waukesha, WI, USA). All acquisitions
were performed with the patient in supine position, in cran-
iocaudal direction, with a z-axis coverage from the diaphrag-
matic dome to the pubic symphysis. Scanning parameters
were adjusted as follows: tube voltage, 120 kVp; beam pitch,
1.375:1; detector configuration, 64 ⋅ 0.625 mm. A z-axis tube
current modulation (Smart mA, GE Healthcare) was applied
with a noise index of 28 (min/max tube current: 200/600
mAs) as recommended by the manufacturer for abdominal
CT.
Contrast media (Iobitridol 350, Guerbet, France) was
intravenously administered through an 18-gauge antecubital
intravenous access using an automated dual-syringe power
injector (Stellant D; Medrad Inc, Warrendale, PA) at a flux
of 4.5 mL/s followed by a 50 mL saline flush at the same
flow rate. Each patient received 0.7 g of iodine [gI] per kg of
LBW. The resulting value was subsequently divided by CM
concentration to obtain the exact CM volume to be injected,
as follows:
𝐶𝑀V𝑜𝑙𝑢𝑚𝑒(𝑚𝑙) = 0.7 ∙ 𝐿𝐵𝑊350 ∙ 1000 (5)
Scan timing was determined by a 120 kVp bolus tracking
technique (SmartPrep, GE Healthcare) by placing a region-
of-interest (ROI) in the abdominal aorta at the level of the
celiac tripod. The threshold for scan initiation was set at
an attenuation of100 Hounsfield Units (HU). A triphasic
acquisition protocol was applied as follows: the late arterial
phase was acquired 18s after reaching the threshold, while the
portal venous phase and the equilibrium were acquired 70s
and 180s after reaching the threshold, respectively. For the
specific purpose of this study only the portal venous phase
was analyzed.
2.4. CT Image Reconstruction. Image datasets were recon-
structed at the CT scanner console with the following param-
eters: section thickness of 1.25 mm and spacing of 1.25 mm.
Iterative reconstruction (ASiR; GEHealthcare) was applied at
strength level of 40%, as recommended by the vendor.
2.5. Objective ImageQuality Analysis. All datasets were trans-
ferred to an independent workstation (Advantage worksta-
tion 4.5, GEHealthcare). A reader with 10 years of experience
in abdominal imaging performed the image analysis in
axial sections. HU was measured by placing a circular ROI
of approximately 1 cm2 (mean pixel number: 600; range:
200-1200) in the liver (n = 3 ROIs; segment II, IVa, and
VII), suprarenal abdominal aorta, portal vein, and left psoas
muscle. An additional ROI was placed in the subcutaneous
fat and standard deviation (SD) was calculated and defined
as image noise. To ensure data robustness, all measurements
were repeated 3 times and subsequently averaged. Liver HU
was defined as the mean of the 3 averaged ROIs.
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Table 1: Patient characteristics.
Parameter Group A Group B P value
Number of patients 26 29 -
Male-to-female ratio 11:15 16:13 -
Age, years 61.54 ± 11.06 59.31 ± 10.67 0.493
Weight, kg 109.54 ± 20.93 109.38 ± 15.01 0.989
Height, m 165.85 ± 7.67 166.03 ± 13.94 0.469
BMI, kg/m2 39.79 ± 6.55 38.75 ± 4.11 0.501
LBW, kg 62.30 ± 10.15 61.21 ± 11.07 0.705
CM volume, mL 123.65 ± 20.19 119.79 ± 23.79 0.532
Data are mean ± SD.
BMI = body mass index; LBW = lean body weight; CM = contrast media
Table 2: Quantitative image analysis.
Group A Group B P value
CNR
Liver 3.75 ± 2.31 2.83 ± 2.65 0.177
Aorta 8.15 ± 4.19 7.95 ± 3.99 0.722
Portal Vein 7.82 ± 7.24 7.27 ± 3.76 0.967
CEI
Liver (HU) 51.45 ± 9.79 41.79 ± 14.32 0.007
Data are mean ± SD
CEI = contrast enhancement index; CNR = contrast-to-noise ratio
Liver, aorta, and portal vein contrast-to-noise ratio
(CNR) was calculated as follows:
𝐶𝑁𝑅𝑙𝑖V𝑒𝑟 = 𝐻𝑈𝑙𝑖V𝑒𝑟 − 𝐻𝑈𝑚𝑢𝑠𝑐𝑙𝑒𝑁𝑜𝑖𝑠𝑒
𝐶𝑁𝑅𝑎𝑜𝑟𝑡𝑎 = 𝐻𝑈𝑎𝑜𝑟𝑡𝑎 − 𝐻𝑈𝑚𝑢𝑠𝑐𝑙𝑒𝑁𝑜𝑖𝑠𝑒
𝐶𝑁𝑅𝑝𝑜𝑟𝑡𝑎𝑙 V𝑒𝑖𝑛 = 𝐻𝑈𝑝𝑜𝑟𝑡𝑎𝑙 V𝑒𝑖𝑛 − 𝐻𝑈𝑚𝑢𝑠𝑐𝑙𝑒𝑁𝑜𝑖𝑠𝑒
(6)
The liver contrast enhancement was quantified by calculating
the contrast enhancement index (CEI) as follows [18]:
𝐶𝐸𝐼 = 𝐻𝑈𝑒𝑛ℎ𝑎𝑛𝑐𝑒𝑑 − 𝐻𝑈𝑢𝑛𝑒𝑛ℎ𝑎𝑛𝑐𝑒𝑑 (7)
2.6. Subjective Image Quality Analysis. Subjective analysis
was performed by two radiologists in consensus with three
and seven years of experience in abdominal CT imaging,
respectively. Readers were blinded to the formula used to
calculate the LBW. The datasets were initially displayed at a
preset window width of 400 HU and window level of 40 HU;
however, readers were allowed to manually adjust window
width and level settings according to their preferences.
Readers were asked to rate the enhancement of liver,
kidneys, and pancreas bymeans of a 5-point Likert scale [20]:
1 = very poor; 2 = poor; 3 = fair; 4 = good; 5 = excellent.
2.7. Statistical Analysis. All statistical analyses were per-
formed by using the MedCalc5 Satistical Software ver-
sion 17.9.7 (MedCalc Software bvba, Ostend, Belgium;
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Figure 1: Graph bars of CNR of liver, aorta, and portal vein for
groups A and B. All the differences between the two groups were
not significant.
http://www.medcalc.org; 2017). Variables are expressed as
mean ± SD.The Kolmogorov-Smirnov test was used to assess
data distribution. Patient characteristics, CNRs, CEI, and
subjective image quality, were compared between the two
groups. In case of normally distributed data, Student’s t-
test was applied. In case of nonnormally distributed data,
Wilcoxon signed-rank test was used. Statistical significance
was defined as a two-tailed P value < 0.05.
3. Results
3.1. Study Population. From an initial population of 68
individuals, 13 patients were excluded from the study due to
an inadequate intravenous access. Thus, the final population
consisted of 55 patients. Patients underwent CT for oncologic
follow-up (n = 41), suspected cancer (n = 4), cirrhosis (n =
3), abdominal pain (n = 3), hepatic haemangiomas (n = 1),
echinococcal cyst (n = 1), unexplained persistent fever (n =
1), and urinary infection (n = 1).
There were no significant differences in patient charac-
teristics between the two groups. Patient characteristics are
reported in Table 1.
3.2. Contrast Media Dose. Group A received 43.28 ± 7.07 gI,
corresponding to 123.65 ± 20.19 mL of CM.
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Figure 2: Axial CT scan of unenhanced (a) and portal venous phase (b) of a 63-year-old female (LBW: 49.1 kg; CM volume: 98 mL) allocated
in Group A and unenhanced (c) and portal venous phase (d) of a 73-year-old female (LBW: 47.7 kg; CM volume: 95 mL) allocated in Group
B. The patient in Group A achieved a higher CEI (62.0 HU) compared to the patient in Group B (40.8 HU). Windows settings: width: 400;
level: 40.
Group B received 41.93 ± 8.32 gI, corresponding to 119.79± 23.79 mL of CM. No statistical differences were observed
between the two groups (P = 0.532) as shown in Table 1.
3.3. Objective ImageQuality. Comprehensive objective image
quality data are reported in Table 2.
Group A achieved slightly higher liver CNR (3.75 ± 2.31
vs. 2.83 ± 2.65), aortic CNR (8.15 ± 4.19 vs. 7.95 ± 3.99), and
portal vein CNR (7.82 ± 7.24 vs. 7.27 ± 3.76); however, none
of the values reached statistical significance (all 𝑃 ≥ 0.177) as
shown in Figure 1.
Group A provided significantly higher CEI (51.45 ± 9.79)
compared to Group B (41.79 ± 14.32, 𝑃 = 0.007), Figure 2.
3.4. Subjective Image Quality. Detailed results are displayed
in Figure 3. Group A and Group B returned comparable
overall enhancement values (3.54 and vs 3.20, all 𝑃 ≥0.199). In Group A, two patients (7.7%) scored poor contrast
enhancement while 1 patient (3.8%) achieved very poor
Group A Group B
Subjective Image Quality
P=0.
P=0.1 P=0.
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Figure 3: Subjective image analysis results. Liver, kidneys, and
pancreas enhancement was ranked on a 5-point Likert scale. Graph
bars of subjective image quality scores achieved by liver, kidneys, and
pancreas in the two groups. All the differences were not significant.
contrast enhancement. In Group B, three patients (10.3%)
achieved poor contrast enhancement and other three patients
(10.3%) scored a very poor contrast enhancement.
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4. Discussion
The aim of our study was to compare, on CT of the abdomen,
the performance of James and Boer formula in terms of image
quality and parenchymal enhancement in obese patients.
CNR of liver, aorta, and portal vein and liver CEI and image
quality have been analyzed on portal venous phase. Our
results demonstrate both formulas achieve comparable image
quality, while Boer formula allowed for higher enhancement
compared to James formula.
A recently published multicentre study [9], performed
on 1342 patients with a normal BMI, established LBW as
the best parameter to determine the optimal amount of CM
in CT examinations. Authors determined aortic and hepatic
attenuation during unenhanced, hepatic arterial phase, and
portal venous phase and, among different body size parame-
ters, LBW exhibited the strongest correlation with aortic and
hepatic enhancement. In the aforementioned investigation,
LBW was estimated by James formula. However, Nyman
[19] pointed out the limitations of such formula in assessing
LBW in obese patients, proposing Boer formula as a reli-
able method do achieve a consistent LBW measurement in
obese population due to its linear function. Results of our
investigations did not find statistical significant differences
in terms of CNR between the two formulas, despite the
fact that our patient population had an average BMI slightly
below 40 kg/m2. A possible explanation could be due to
the fact that LBW calculation with James formula reaches a
plateau at a BMI of about 37 and 43 kg/m2 in women and
men, respectively.Therefore, despite being classified as obese,
our study population was still the BMI threshold making
James formula ineffective. Thus, this result is in accordance
with Nyman’s statement [19] and, at the same time, further
strengthens the validity of James formula in calculating LBW
for a large percentage of patients [10, 13, 21] and in other
imaging modalities such as hybrid PET/CT [22]. Both Ho
et al. [10] and Kondo et al. [13] investigations achieved
optimal vascular and hepatic enhancement on portal venous
phase and unenhanced and portal venous phase, respectively,
administrating CM dose estimated on LBW calculated with
James formula.
Interestingly, the implementation of Boer formula pro-
vided a significantly higher CEI compare to James formula.
A CEI of at least 50 HU is advisable in clinical practice for
adequate liver imaging and diagnostic purposes [4, 23]. Some
hypotheses can be formulated to try to explain this result,
such as Boer formula, which allows for a more appropriate
estimation of LBW in obese patients, or the slightly higher
amount of CM administered in Group A, which could have
led to higher CEI. However, the first hypothesis is in dis-
cordance with the nonstatistical differences in terms of BMI
and LBW in both groups (Table 1) while the nonsignificant
higher amount of CM in Group A seems to contradict the
second hypothesis, given that the explanation of these results
is difficult to be determined and it is possible that other
patient-related variables, such as cardiac output [4, 5, 13, 24],
have played a role in providing this result.
Both Boer and James formula provided a fair-to-optimal
contrast enhancement of liver, kidneys, and pancreas in the
vast majority of patients. 11% of patients whose LBW was
calculated by Boer formula reported a poor or very poor
enhancement while this percentage almost doubled (21%) in
the Group in which James formula was applied. These results
are quite in accordance with the aforementioned objective
image quality results and give strength to the assumption
that Boer formula outperforms James formula either in
terms of subjective or in terms of objective image quality,
allowing for a more reliable image evaluation since it is well
established that an adequate contrast enhancement is crucial
for multiple clinical evaluation of the abdomen, especially
when parenchymal lesions are suspected and a multiphasic
CT examination is required [25, 26].
Our study has some limitations. First, this investigation
was conducted on a small sample size population and further
studies on a larger sample size are advisable to further
confirm our findings. Second, this preliminary study was
only focused on image quality and diagnostic performance
was not assessed. Third, both female and male patients were
included in Group A and Group B, despite the fact that the
two formulas applied to calculate LBW also take into account
patient sex as well; a subgroup analysis on sex-separated
cohorts would be advisable in future investigations.
In conclusion, Boer formula should be the method of
choice for LBW estimation in class II obese patients, leading
to an accurate CM amount calculation and an optimal liver
contrast enhancement.
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